Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease

Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants

(2020) Kenji Watanabe et al.   JOURNAL OF GASTROENTEROLOGY

Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet’s disease

(2019) Naomi Sugimura et al.   DIGESTIVE AND LIVER DISEASE

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease

(2018) Jihye Park et al.   Gut and Liver

Updated treatment strategies for intestinal Behçet’s disease

(2018) Yong Eun Park et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Interleukin (IL-6) Immunotherapy

(2017) Toshio Tanaka et al.   Cold Spring Harbor Perspectives in Biology

Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcetʼs Syndrome

(2016) Ibrahim Hatemi et al.   MEDICINE

Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease

(2016) Toshifumi Hibi et al.   MEDICINE

Adalimumab for the Treatment of Japanese Patients With Intestinal Behçet’s Disease

(2015) Satoshi Tanida et al.   Clinical Gastroenterology and Hepatology

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

(2015) H. Vallet et al.   JOURNAL OF AUTOIMMUNITY

Is there a relation between clinical disease activity and acute phase response in Behcet's disease?

(2013) Mehmet Melikoglu et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

Identification of a susceptibility locus inSTAT4for Behçet's disease in Han Chinese in a genome-wide association study

(2012) Shengping Hou et al.   ARTHRITIS AND RHEUMATISM

Clinical Course of Intestinal Behcet’s Disease During the First Five Years

(2012) Yoon Suk Jung et al.   DIGESTIVE DISEASES AND SCIENCES

Long-Term Clinical Outcomes and Factors Predictive of Relapse After 5-Aminosalicylate or Sulfasalazine Therapy in Patients With Intestinal Behcet Disease

(2012) Yoon Suk Jung et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis

(2011) T. Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcetʼs disease

(2011) Yoon Suk Jung et al.   INFLAMMATORY BOWEL DISEASES

Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohnʼs Disease

(2011) Toshifumi Hibi et al.   INFLAMMATORY BOWEL DISEASES

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

(2010) Nobuhisa Mizuki et al.   NATURE GENETICS

Genome-wide association study identifies variants in the MHC class I, IL10 and IL23R-IL12RB2 regions associated with Behçet's disease

(2010) Elaine F Remmers et al.   NATURE GENETICS

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17–producing effector T helper cells in vivo

(2009) Mandy J McGeachy et al.   NATURE IMMUNOLOGY

Interleukin-17 Promotes Autoimmunity by Triggering a Positive-Feedback Loop via Interleukin-6 Induction

(2008) Hideki Ogura et al.   IMMUNITY

Long-term outcome after infliximab for refractory ulcerative colitis

(2008) Marc Ferrante et al.   Journal of Crohns & Colitis